Proactive Investors - Run By Investors For Investors

Medlab Clinical collaborates with Chronic Pain Australia

Medlab has two cannabis-based medicines, NanaBis™ and NanaBidial™.
collaboration concept
NanaBis™ is currently in clinical trial at Royal North Shore Hospital

Medlab Clinical Ltd (ASX:MDC) has entered into a collaborative agreement with Chronic Pain Australia to promote the education of medicinal cannabis to doctors and patients.

Specifically,  to people living with chronic pain and their relevant healthcare providers.

The roll-out commences this month.

READ: Medlab CEO presents clinical NanaBis update to medical practitioners

Medlab’s CEO Dr Sean Hall said: “We openly welcome this alliance with Chronic Pain Australia, we understand that pain management has to extend beyond opioids, their derivatives, and lifestyle management; new therapies such as NanaBis™ equate to more options, and together we can work on better patient outcomes.”

Chronic Pain Australia is a not-for-profit consumer-lead organisation dedicated to reducing health and social barriers faced by people living with chronic pain.

It supports over 35,000 people living with chronic pain each month and has partnered with the Australian Pain Society and Faculty of Pain Medicine to develop Australia's first National Pain Strategy.

NanaBis™ in clinical trial at Royal North Shore Hospital

Medlab has two cannabis-based medicines, NanaBis™ and NanaBidial™, which contain formulations of tetrahydrocannabinol (THC) and cannabidiol (CBD).

NanaBis™ has a 1:1 ratio of CBD:THC and NanaBidial™ has a 18:2 ratio of CBD:THC.

NanaBis™ is currently in clinical trial at Royal North Shore Hospital.

Notably, both medicines are available to Australian patients for compassionate use under the government Special Access Scheme (SAS).

Proactive caught up with Medlab last month to get an update on the company, including NRGBiotic™, a probiotic.

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full MDC profile View Profile

Medlab Clinical Ltd Timeline

Related Articles

The R&D programme is intended to address the increasing prevalence of obesity and diabetes using smart siRNA
October 31 2018
The health sciences company noted that the plan was formulated at a recently held two-day intensive workshop which together leading scientific teams from the QIMR Berghofer Medical Research Institute in Brisbane and Murdoch University in Perth
A WeedMD greenhouse
January 22 2019
WeedMD produces cannabis and cannabis oil for both the medical and adult-use markets
A cannabis plant shown next to an oil-based product
08:30
THC is executing medicinal cannabis strategy in Australia, New Zealand and Canada and is looking to Asian markets.

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use